CY1124059T1 - Αζαβενζιμιδαζολια και χρηση αυτων ως ρυθμιστες υποδοχεα ampa - Google Patents

Αζαβενζιμιδαζολια και χρηση αυτων ως ρυθμιστες υποδοχεα ampa

Info

Publication number
CY1124059T1
CY1124059T1 CY20211100354T CY211100354T CY1124059T1 CY 1124059 T1 CY1124059 T1 CY 1124059T1 CY 20211100354 T CY20211100354 T CY 20211100354T CY 211100354 T CY211100354 T CY 211100354T CY 1124059 T1 CY1124059 T1 CY 1124059T1
Authority
CY
Cyprus
Prior art keywords
azabenzimidazoles
ampa receptor
receptor regulators
compounds
formula
Prior art date
Application number
CY20211100354T
Other languages
English (en)
Inventor
Cynthia G.B. BERRY
Gang Chen
Fabrice Loic JOURDAN
Terry Patrick LEBOLD
Miguel Angel PENA PIÑÓN
Suchitra Ravula
Devin M. Swanson
Dongpei Wu
Wei Zhang
Michael K. Ameriks
Bradley M. SAVALL
David Wei LIN
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of CY1124059T1 publication Critical patent/CY1124059T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Παρεχόμενες στο παρόν είναι ενώσεις του Τύπου (Ι) και φαρμακευτικώς αποδεκτά άλατα, Ν-οξείδια ή διαλυτώματα αυτών. Επίσης παρεχόμενες στο παρόν είναι φαρμακευτικές συνθέσεις που περιλαμβάνουν ενώσεις του Τύπου (Ι) και μέθοδοι χρήσης ενώσεων του Τύπου (Ι).
CY20211100354T 2015-04-29 2021-04-23 Αζαβενζιμιδαζολια και χρηση αυτων ως ρυθμιστες υποδοχεα ampa CY1124059T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562154313P 2015-04-29 2015-04-29
PCT/US2016/029801 WO2016176460A1 (en) 2015-04-29 2016-04-28 Azabenzimidazoles and their use as ampa receptor modulators

Publications (1)

Publication Number Publication Date
CY1124059T1 true CY1124059T1 (el) 2022-05-27

Family

ID=56008859

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20211100354T CY1124059T1 (el) 2015-04-29 2021-04-23 Αζαβενζιμιδαζολια και χρηση αυτων ως ρυθμιστες υποδοχεα ampa

Country Status (39)

Country Link
US (4) US11312712B2 (el)
EP (3) EP3901153A1 (el)
JP (2) JP6800886B2 (el)
KR (2) KR20240017991A (el)
CN (1) CN107835814B (el)
AR (1) AR104447A1 (el)
AU (2) AU2016255434C1 (el)
BR (2) BR122023023802A2 (el)
CA (1) CA2983826A1 (el)
CO (1) CO2017011017A2 (el)
CR (1) CR20170484A (el)
CY (1) CY1124059T1 (el)
DK (1) DK3288940T5 (el)
EA (1) EA033281B1 (el)
EC (1) ECSP17074645A (el)
ES (1) ES2865330T3 (el)
GT (1) GT201700231A (el)
HK (1) HK1252249A1 (el)
HR (1) HRP20210403T1 (el)
HU (1) HUE053943T2 (el)
IL (1) IL254848B (el)
JO (1) JO3654B1 (el)
LT (1) LT3288940T (el)
MA (1) MA41988B1 (el)
MD (1) MD3288940T2 (el)
MX (1) MX2017013886A (el)
MY (1) MY194104A (el)
NI (1) NI201700129A (el)
PH (1) PH12017501816A1 (el)
PL (1) PL3288940T3 (el)
PT (1) PT3288940T (el)
RS (1) RS61688B1 (el)
SG (1) SG11201708190UA (el)
SI (1) SI3288940T1 (el)
TW (1) TWI706952B (el)
UA (1) UA120304C2 (el)
UY (1) UY36654A (el)
WO (1) WO2016176460A1 (el)
ZA (1) ZA201708065B (el)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20170141768A (ko) * 2015-04-29 2017-12-26 얀센 파마슈티카 엔.브이. 이미다조피라진 및 피라졸로피리미딘 및 ampa 수용체 조절제로서의 이의 용도
CN107383004B (zh) * 2017-07-05 2020-04-17 浙江大学 2-氨基咪唑并吡啶类衍生物及制备和应用
CN111315735B (zh) * 2017-09-04 2024-03-08 C4医药公司 二氢苯并咪唑酮
EP3693360B1 (en) 2017-10-06 2023-12-13 Takeda Pharmaceutical Company Limited Heterocyclic compounds
RS65335B1 (sr) 2018-10-05 2024-04-30 Annapurna Bio Inc Jedinjenja i kompozicije za lečenje stanja povezanih sa aktivnošću receptora apj
AU2019373416A1 (en) * 2018-10-30 2021-06-10 Repare Therapeutics Inc. Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use as ATR kinase inhibitors
MX2022000854A (es) * 2019-07-22 2022-02-10 Repare Therapeutics Inc Derivados de 2-morfolinopiridina sustituidos como inhibidores de la cinasa atr.
JP2023554393A (ja) * 2020-12-16 2023-12-27 アイエフエム デュー インコーポレイテッド Ｓｔｉｎｇ活性に関連する状態を治療するための化合物および組成物
CN114591338B (zh) * 2022-03-31 2023-05-09 苏州欧康维视生物科技有限公司 一种Syk和VEGFR2双靶点抑制剂的制备方法及其用途
CN115304599A (zh) * 2022-09-20 2022-11-08 浙大宁波理工学院 一种3-溴-6-异丙基-1氢-哌咯[2，3-b]并吡啶及其制备方法

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS55167282A (en) 1979-06-12 1980-12-26 Fujisawa Pharmaceut Co Ltd Piperazine derivative or its salt and its preparation
CN1051313A (zh) 1990-11-07 1991-05-15 鞍山市振东工业尼龙厂 尼龙球磨罐及其热装工艺
GB9210400D0 (en) * 1992-05-15 1992-07-01 Merck Sharp & Dohme Therapeutic agents
TW251284B (el) 1992-11-02 1995-07-11 Pfizer
US5688809A (en) 1994-02-10 1997-11-18 Pfizer Inc. 5-heteroarylindole derivatives
US5565483A (en) 1995-06-07 1996-10-15 Bristol-Myers Squibb Company 3-substituted oxindole derivatives as potassium channel modulators
UA54403C2 (uk) 1996-10-01 2003-03-17 Н'Юросерч А/С Похідні індол-2,3-діон-3-оксиму, фармацевтична композиція, спосіб лікування розладу чи захворювання ссавців, у тому числі людини та спосіб одержання похідних індол-2,3-діон-3-оксиму
DE19812331A1 (de) 1998-03-20 1999-09-23 Merck Patent Gmbh Piperidinderivate
JP2002519373A (ja) 1998-07-02 2002-07-02 エーザイ株式会社 製薬組成物及びそれらの使用
EP1139754A4 (en) 1998-12-31 2002-12-18 Sugen Inc 3-HETEROARYLIDENYL-2-INDOLINONE COMPOUNDS FOR MODULATION OF PROTEIN KINASE ACTIVITY AND IN CANCER CHEMOTHERAPY
GB0018473D0 (en) 2000-07-27 2000-09-13 Merck Sharp & Dohme Therapeutic agents
AU2001282865A1 (en) 2000-08-11 2002-02-25 Eli Lilly And Company Heterocyclic sulfonamide derivatives
US6548576B1 (en) 2001-11-07 2003-04-15 Bourns, Inc. Epoxy formulation adapted to be used in conjunction with no-lead solder in electronic components
GT200500185A (es) 2004-08-09 2006-04-10 Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos
CN101052640B (zh) 2004-09-03 2011-05-11 默克雪兰诺有限公司 吡啶亚甲基唑烷酮类及其作为磷酸肌醇抑制剂的用途
DE602006019119D1 (de) 2005-09-30 2011-02-03 Glaxo Group Ltd Verbindungen mit aktivität am m1-rezeptor und ihre verwendung in der medizin
WO2007135529A2 (en) * 2006-05-23 2007-11-29 Pfizer Products Inc. Azabenzimidazolyl compounds as mglur2 potentiators
DE602007013450D1 (de) 2006-11-03 2011-05-05 Glaxo Group Ltd Verbindungen, die den ampa-rezeptor verstärken, und deren anwendung in der medizin
WO2008113795A1 (en) 2007-03-20 2008-09-25 Glaxo Group Limited Compounds which potentiate ampa receptor and uses thereof in medicine
GB0711089D0 (en) 2007-06-08 2007-07-18 Glaxo Group Ltd Compounds
GB0716292D0 (en) 2007-08-21 2007-09-26 Biofocus Dpi Ltd Imidazopyrazine compounds
WO2009067607A2 (en) 2007-11-20 2009-05-28 Memory Pharmaceuticals Corporation Combinations of pde4 inhibitors and antipsychotics for the treatment of psychotic disorders
US8450343B2 (en) 2007-12-06 2013-05-28 Xianhai Huang Gamma secretase modulators
TW201012803A (en) 2008-06-06 2010-04-01 Organon Nv Heterocyclic derivatives
WO2010005528A2 (en) * 2008-06-30 2010-01-14 Ironwood Pharmaceuticals Incorporated Pyrrolopyridine carboxylic acid derivatives
GB0822425D0 (en) 2008-12-09 2009-01-14 Glaxo Group Ltd Compounds
GB0822981D0 (en) 2008-12-17 2009-01-21 Summit Corp Plc Compounds for treatment of duchenne muscular dystrophy
WO2011056985A2 (en) 2009-11-04 2011-05-12 Gilead Sciences, Inc. Substituted heterocyclic compounds
WO2011156245A2 (en) 2010-06-09 2011-12-15 Merck Sharp & Dohme Corp. Positive allosteric modulators of mglur2
PT2603513T (pt) 2010-08-10 2020-06-08 Takeda Pharmaceuticals Co Composto heterocíclico e sua utilização como modulador alostérico positivo do recetor de ampa
US8993779B2 (en) 2010-08-12 2015-03-31 Merck Sharp & Dohme Corp. Positive allosteric modulators of MGLUR2
BR112014010368A2 (pt) 2011-10-31 2017-04-25 Xenon Pharmaceuticals Inc biaril éter sulfonamidas e seu uso como agentes terapêuticos
WO2013130501A1 (en) 2012-03-01 2013-09-06 The Board Of Regents Of The University Of Texas System Bivalent ampa receptor positive allosteric modulators
GB201205669D0 (en) * 2012-03-30 2012-05-16 Agency Science Tech & Res Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof
JO3225B1 (ar) 2012-11-27 2018-03-08 Lilly Co Eli 6-((s)-1-{1-[5-(2-هيدروكسي-إيثوكسي)-بيريدين-2-يل]-1h-بيرازول-3-يل}إيثيل)-3h-1 ، 3-بنزو ثيازول-2- أون باعتباره مضاد مستقبل ampa يعتمد على tarp- جاما 8
MX2015010714A (es) 2013-02-19 2016-06-14 Pfizer Compuestos de azabencimidazol.

Also Published As

Publication number Publication date
UY36654A (es) 2016-10-31
SG11201708190UA (en) 2017-11-29
EP3288940B9 (en) 2021-07-21
AU2016255434C1 (en) 2021-09-23
IL254848B (en) 2021-01-31
ES2865330T3 (es) 2021-10-15
HUE053943T2 (hu) 2021-08-30
EP3288940A1 (en) 2018-03-07
EP4144736A1 (en) 2023-03-08
MA41988B1 (fr) 2021-03-31
JP7026194B2 (ja) 2022-02-25
PH12017501816A1 (en) 2018-04-23
US20230114165A1 (en) 2023-04-13
JO3654B1 (ar) 2020-08-27
CN107835814A (zh) 2018-03-23
DK3288940T3 (da) 2021-05-25
PT3288940T (pt) 2021-04-30
JP2018518462A (ja) 2018-07-12
IL254848A0 (en) 2017-12-31
UA120304C2 (uk) 2019-11-11
NI201700129A (es) 2019-05-10
AU2016255434A1 (en) 2017-10-26
MX2017013886A (es) 2018-03-12
MY194104A (en) 2022-11-11
TW201708217A (zh) 2017-03-01
LT3288940T (lt) 2021-05-10
JP2021042230A (ja) 2021-03-18
EP3901153A1 (en) 2021-10-27
EA033281B1 (ru) 2019-09-30
KR20240017991A (ko) 2024-02-08
PL3288940T3 (pl) 2021-07-12
AU2020210231B2 (en) 2021-07-22
ZA201708065B (en) 2019-09-25
WO2016176460A1 (en) 2016-11-03
US20180118740A1 (en) 2018-05-03
CN107835814B (zh) 2021-07-23
MD3288940T2 (ro) 2021-08-31
RS61688B1 (sr) 2021-05-31
HRP20210403T1 (hr) 2021-10-29
EP3288940B1 (en) 2021-02-24
HK1252249A1 (zh) 2019-05-24
AU2020210231A1 (en) 2020-08-20
CR20170484A (es) 2018-02-26
ECSP17074645A (es) 2018-02-28
DK3288940T5 (da) 2021-09-20
BR112017023147A2 (pt) 2018-07-10
KR20170140382A (ko) 2017-12-20
AR104447A1 (es) 2017-07-19
SI3288940T1 (sl) 2021-07-30
CA2983826A1 (en) 2016-11-03
BR112017023147B1 (pt) 2024-04-30
US11312712B2 (en) 2022-04-26
BR122023023802A2 (pt) 2023-12-26
NZ736057A (en) 2023-08-25
US20210284641A1 (en) 2021-09-16
MA41988A (fr) 2018-07-03
TWI706952B (zh) 2020-10-11
US20230110576A1 (en) 2023-04-13
EA201792374A1 (ru) 2018-05-31
GT201700231A (es) 2018-12-20
AU2016255434B2 (en) 2020-05-14
JP6800886B2 (ja) 2020-12-16
CO2017011017A2 (es) 2018-03-20

Similar Documents

Publication Publication Date Title
CY1124059T1 (el) Αζαβενζιμιδαζολια και χρηση αυτων ως ρυθμιστες υποδοχεα ampa
CY1123994T1 (el) Δικυκλικες-συντηγμενες ενωσεις ετεροαρυλιου ή αρυλιου ως ρυθμιστες της irak4
CY1121413T1 (el) Διυδροπυρρολοπυριδινης αναστολεις ror-γαμμα
CL2018003701A1 (es) Compuestos heterocíclicos como inmunomoduladores.
CY1121195T1 (el) Παραγωγα τετραϋδροναφθαλενιου που αναστελλουνπρωτεϊνη mcl-1
CY1121694T1 (el) Ενωσεις δι-κυκλικου-συντηγμενου ετεροαρυλιου ή αρυλιου και η χρηση αυτων ως αναστολεις irak4
CY1118379T1 (el) Αναστολεις ιου ηπατιτιδας c
EA202091115A1 (ru) Производные хиназолина, применяемые для лечения вич
CY1120742T1 (el) Ρυθμιστες του υποδοχεα χ ηπατος (lxr) για τη θεραπεια δερματικων ασθενειων, διαταραχων και καταστασεων
CY1122613T1 (el) Παραγωγα 4-οξο-3,4-διυδρο-1,2,3-βενζοτριαζινης ως ρυθμιστες toy gpr139
EA201791304A1 (ru) Производные изохинолина для лечения вич
MX2017013877A (es) Compuestos de benzimidazolona y benzotiazolona y su uso como moduladores del receptor ampa.
EA201991700A1 (ru) Селективные ингибиторы jak1
CY1121596T1 (el) Αμιδια βενζοξαζινονης ως αλατοκορτικοειδεις ρυθμιστες υποδοχεα
EA201691674A1 (ru) 1,2-замещенные циклопентаны в качестве антагонистов рецептора орексина
TR201900680T4 (tr) CXCR3 Reseptör modülatörleri olarak hidroksialkil- piperazin türevleri.
CY1123494T1 (el) Enωσeiς etepoapyλo-kapboξamiδioy ως anaσtoλeiς thς ripk2
CO2019004164A2 (es) Compuestos de piridina bicíclicos fusionados y su uso como moduladores de receptores ampa
CY1122321T1 (el) Παραγωγα φθοροϊνδολιου ως θετικοι αλλοστερικοι διαμορφωτες του μουσκαρινικου υποδοχεα μ1
TR201819805T4 (tr) Flavaglin türevleri̇.
CR20160373A (es) Ciclopentanos, tetrahidrofuranos y pirrolidinas sustituidas como antagonistas del receptor de orexina
CY1123185T1 (el) Παραγωγα ινδολιου
CO2019004143A2 (es) Compuestos azaheterocíclicos fusionados y su uso como moduladores de los receptores ampa
MX369806B (es) Compuestos de indolona y su uso como moduladores del receptor ampa.
EA201891680A1 (ru) Производные индана в качестве модуляторов mglur7